第一三共ADC药物R-DXd获国家药监局突破性疗法认定

Core Viewpoint - Raludotatug Deruxtecan (R-DXd, DS-6000a) has received Breakthrough Therapy Designation (BTD) from the China National Medical Products Administration (NMPA) for the treatment of adult patients with platinum-resistant epithelial ovarian cancer, primary peritoneal cancer, or fallopian tube cancer who have previously been treated with Bevacizumab and express CDH6 [1] Group 1 - Raludotatug Deruxtecan is developed by Daiichi Sankyo and co-developed with Merck [1] - The drug is a CDH6-targeted antibody-drug conjugate (ADC) [1]